Non-MALT marginal zone lymphoma

Current Opinion in Hematology

Volumn 18, Issue 4, 2011, Pages 273-279

  Thieblemont, Catherine ^a,b,c   Davi, Frederic ^d   Noguera, Maria Elena ^b,c,e   Brière, Josette ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Laboratory of Hematology   (France)

Author keywords

diagnostic criteria; new therapeutics; nodal marginal zone lymphoma; splenic marginal zone lymphoma

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; BORTEZOMIB; CLADRIBINE; CRYOGLOBULIN; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; PEGINTERFERON ALPHA; PROTEIN BCL 10; RIBAVIRIN; RITUXIMAB; VELTUZUMAB;

ADJUVANT CHEMOTHERAPY; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE MARKER; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C VIRUS; HUMAN; HYPERSPLENISM; IMMUNOGLOBULIN HEAVY CHAIN GENE; LACTATE DEHYDROGENASE BLOOD LEVEL; MALT 1 GENE; NODAL MARGINAL ZONE LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; VON WILLEBRAND DISEASE;

HUMANS; LYMPH NODES; LYMPHOMA, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; SPLEEN;

EID: 79958828980     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283477815     Document Type: Article

References (52)

1. Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol 2009; 27:267-285.
2. Swerdow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon; 2008.
3. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95:1950-1956. (Pubitemid 30151631)
4. Oscier D, Owen R, Johnson S. Splenic marginal zone lymphoma. Blood Rev 2005; 19:39-51. (Pubitemid 39574248)
5. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 2002; 3:41-47.
6. Traverse-Glehen A, Felman P, Callet-Bauchu E, et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology 2006; 48:162-173.
7. Arcaini L, Lucioni M, Boveri E, Paulli M. Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease. Eur J Haematol 2009; 83:165-174.
8. Arcaini L, Burcheri S, Rossi A, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 2007; 18:346-350. (Pubitemid 46323104)
9. Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist 2006; 11:285-291.
10. Arcaini L, PaulliM, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004; 100:107-115. (Pubitemid 37553545)
11. Hermine O, Lefrere F, Bronowicki J, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 11:89-94. (Pubitemid 34753478)
12. Bates I, Bedu-Addo G, Jarrett RF, et al. B-lymphotropic viruses in a novel tropical splenic lymphoma. Br J Haematol 2001; 112:161-166. (Pubitemid 32151164)
13. Arcaini L, Zibellini S, Passamonti F, et al. Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells Mol Dis 2009; 42:286-291.
14. Traverse-Glehen A, Davi F, Ben Simon E, et al. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica 2005; 90:470-478. (Pubitemid 40592889)
15. Zibellini S, Capello D, Forconi F, et al. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica 2010; 95:1792-1796.
16. Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002; 99:1299-1304. (Pubitemid 34547084)
17. Traverse-Glehen A, Verney A, Baseggio L, et al. Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone Bcell lymphomas suggests a particular B-cell origin. Leukemia 2007; 21: 1821-1824. (Pubitemid 47086773)
18. Saadoun D, Boyer O, Trebeden-Negre H, et al. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. J Hepatol 2004; 41:1031-1037. (Pubitemid 39575672)
19. Morse HC, Kearney JF, Isaacson PG, et al. Cells of the marginal zone: origins, function and neoplasia. Leukemia Res 2001; 25:169-178. (Pubitemid 32141121)
20. Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003; 4:95-103. (Pubitemid 36193169)
21. Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003; 120:759-764. (Pubitemid 36315095)
22. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008; 22:487-495. (Pubitemid 351386718)
23. Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood 2008; 111:2253-2260. (Pubitemid 351454029)
24. Boveri E, Arcaini L, Merli M, et al. Bone marrow histology in marginal zone Bcell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Ann Oncol 2009; 20:129-136.
25. Callet-Bauchu E, Baseggio L, Felman P, et al. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia 2005; 19:1818-1823. (Pubitemid 41486161)
26. Dierlamm J, Rosenberg C, Stul M, et al. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization. Leukemia 1997; 11:747-758. (Pubitemid 27241257)
27. Sole F, Salido M, Espinet B, et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica 2001; 86:71-77. (Pubitemid 32147054)
28. Salido M, Baro C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010; 116:1479-1488.
29. Corcoran M, Mould S, Orchard J, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene 1999; 18:6271-6277.
30. Cuneo A, Bardi A, Wlodarska I, et al. A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma. Leukemia 2001; 15:1262-1267. (Pubitemid 32776451)
31. Jadayel D, Matutes E, Dyer M, et al. Splenic lymphoma with villous lymphocytes: analysis of bcl-1 rearrangements and expression of the cyclin D1 gene. Blood 1994; 83:3664-3671. (Pubitemid 24175557)
32. Oscier DG, Matutes E, Gardiner A, et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol 1993; 85:487-491. (Pubitemid 23349050)
33. Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood 2011; 117:1595-1604.
34. Cervetti G, Galimberti S, Cecconi N, et al. Role of low-dose 2-CdA in refractory or resistant lymphoplasmocytic lymphoma. J Chemother 2004; 16:388-391. (Pubitemid 39049890)
35. Cheson BD, Friedberg JW, Kahl BS, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10:452-457.
36. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005; 23:6415-6420. (Pubitemid 46218852)
37. Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107:4643-4649. (Pubitemid 43882609)
38. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005; 106:1831-1838. (Pubitemid 41208601)
39. Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of12 cases. Am J Surg Pathol 2001; 25:1268-1276. (Pubitemid 32917120)
40. Kojima M, Inagaki H, Motoori T, et al. Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: study of 65 cases. Cancer Sci 2007; 98:44-49. (Pubitemid 44803919)
41. Petit B, Chaury MP, Le Clorennec C, et al. Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica 2005; 90:200-206. (Pubitemid 40293281)
42. Oh SY, Ryoo BY, Kim WS, et al. Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol 2006; 85:781-786. (Pubitemid 44377875)
43. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of antihepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23:468-473. (Pubitemid 46224223)
44. Chacon J, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100:1648-1654. (Pubitemid 34925141)
45. Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007; 25:127-131. (Pubitemid 47507880)
46. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000; 14:573-575. (Pubitemid 30195446)
47. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107:125-135. (Pubitemid 43941641)
48. Bennett M, Sharma K, Yegena S, et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005; 90:856-858. (Pubitemid 40897232)
49. Katayama Y, Kojima K, Yoshino T, et al. Common clonal origin of lymphocytes and plasma cells in splenic lymphoma with villous lymphocytes. Br J Haematol 1997; 97:626-634. (Pubitemid 27261630)
50. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23:676-684. (Pubitemid 46237441)
51. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009; 27:3346-3353.
52. Thieblemont C, Coiffier B. Management of marginal zone lymphomas. Curr Treat Options Oncol 2006; 7:213-222.